Pulmonary Embolism

This channel includes news and new technology innovations for Pulmonary Embolism. This condition occurs when an artery in the lungs is blocked, usually caused by a blood clot.

Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic Endovascular System in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism (PE).
News | Pulmonary Embolism | August 09, 2021
August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative...
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call.

News | Artificial Intelligence | July 21, 2021
July 21, 2021 — Artificial intelligence (AI)  medical imaging vendors Viz.AI and Avicenna.AI have partnered to enable...
Avicenna.AI announces the introduction of Cina Chest, including AI tools for detection and emergency triage of pulmonary embolism and aortic dissection.
News | Artificial Intelligence | June 07, 2021
June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced that it has received certification in the United...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal...
The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

News | Thrombectomy Devices | January 08, 2021
January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc....
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants...
Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies | October 26, 2020
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding...
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system.
 

News | Pulmonary Embolism | October 23, 2020
October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world...
The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.
News | Coronavirus (COVID-19) | September 11, 2020
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials...
Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

News | Coronavirus (COVID-19) | September 03, 2020
September 3, 2020 — Why so many COVID-19 (SARS-CoV-2) patients get blood clots (thrombosis) remains uncertain. But...
he U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Abiomed Impella RP catheter-based heart pump to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE).  #COVID19 #SARScov2
Feature | Coronavirus (COVID-19) | June 01, 2020
June 1, 2020 — The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the...
Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Feature | Coronavirus (COVID-19) | May 04, 2020
May 4, 2020 — A committee comprised of vascular surgeons, medical physicians and technologists from the University of...
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of...
 Indigo System CAT RX Aspiration Catheter and Penumbra Engine
News | November 08, 2019
November 8, 2019 — Penumbra Inc. announced that the EXTRACT-PE trial successfully met the primary endpoints,...